Renal Denervation: An Update

Sinny Delacroix, Ramesh Chokka, Adam J. Nelson, Steve Nicholls, Stephen G. Worthley

Research output: Contribution to journalArticlepeer-review


Resistant hypertension is a growing cardiovascular problem worldwide and despite significant pharmacological advances medical
management of the pathology remains challenging. In early clinical trials renal denervation, a catheter based therapy that denervates
renal afferent and efferent sympathetic nervous system has demonstrated significant blood pressure reduction in patients with resistant
hypertension. However, Symplicity HTN-3, the recent randomized controlled trial has challenged the efficacy of the procedure and
underscored that there remain key issues to overcome before the procedure can be used as a standard of care in patients with
resistant hypertension. This review provides a balanced update on the recent preclinical and clinical studies in the field and, focuses
on the important advances required to enhance the forward progression of a technique that has the potential to treat this highly
heterogeneous pathology.
Original languageEnglish
Pages (from-to)5-8
JournalJournal of Advanced Therapies and Medical Innovation Sciences
Publication statusPublished or Issued - 2016


  • Percutaneous renal sympathetic denervation
  • Resistant hypertension
  • Radio-frequency ablation
  • Sympathetic nervous system

Cite this